May 26 (Reuters) – Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were instead stolen and sold, prompting the company to warn users not to use products from two affected lots.
• Dexcom said the affected G7 sensors, from lot numbers 1725204004 and 1725069002, had been marked as scrap as they did not meet company standards.
• The sensors were stolen during a destruction process and later sold by third parties, with Dexcom tracing sales to Pharmsource LLC, which is not an authorized distributor.
• One of the affected lots may carry an increased risk of skin infection, while the other lot has a higher chance of producing no readings at all, DexCom said.
• The issue mainly affects users in the United States, and Dexcom said it is notifying customers and offering replacements.
• Dexcom said there have been no reported severe adverse events linked to the stolen sensors.
• The company said it is working with the U.S. Food and Drug Administration and other authorities to investigate the theft.
(Reporting by Kunal Das in Bengaluru; Editing by Vijay Kishore)
